What's Hot This Year in ID Clinical Science 2025
Abstract
The diversity and depth of clinical research in the field of infectious diseases in 2025 were impressive. Multiple new antibiotics were approved, innovative uses of technology to improve patient care were tested, and novel approaches were trialed to address longstanding problems in infectious diseases. Despite this progress, the resurgence of measles in 2025 offers a stark reminder that any progress against infectious diseases can quickly be lost if the principles of infectious diseases and public health are abandoned. Some of the most important clinical trials and trends in infectious diseases over the past year are highlighted in this review.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.